Yongcong Yan
Overview
Explore the profile of Yongcong Yan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Z, Wang W, Yan Y, Ma Z, Xiao Z, Mao K
Int J Surg
. 2025 Mar;
PMID: 40085751
Background: The majority of patients with hepatocellular carcinoma (HCC) miss the opportunity of radical resection, making ICIs-based conversion therapy a primary option. However, challenges persist in predicting response and identifying...
2.
Zhou Z, Yu W, Li H, Shi J, Meng S, Yan Y, et al.
Mol Cancer Res
. 2024 May;
22(9):891-901.
PMID: 38787319
HBV-associated hepatocellular carcinoma (HCC) represents the prevalent form of HCC, with HBx protein being a crucial oncoprotein. Numerous members of the protein tyrosine phosphatase nonreceptor (PTPN) family have been confirmed...
3.
Shi J, Wen K, Mui S, Li H, Liao H, He C, et al.
Clin Transl Oncol
. 2024 Mar;
26(9):2181-2197.
PMID: 38472558
Background: Deregulating cellular metabolism is one of the prominent hallmarks of malignancy, with a critical role in tumor survival and growth. However, the role of reprogramming aspartate metabolism in hepatocellular...
4.
Zhou Z, Chen Z, Zhou Q, Meng S, Shi J, Mui S, et al.
Cancer Sci
. 2024 Mar;
115(5):1587-1601.
PMID: 38438251
Both lysine and arginine methyltransferases are thought to be promising therapeutic targets for malignant tumors, yet how these methyltransferases function in malignant tumors, especially hepatocellular carcinoma (HCC), has not been...
5.
Ma Z, Xiao Z, Yin P, Wen K, Wang W, Yan Y, et al.
Int J Surg
. 2024 Feb;
110(5):2910-2921.
PMID: 38353702
Objective: The objective of this study is to evaluate and compare the survival benefit and safety of surgery following conversion therapy versus surgery alone in patients diagnosed with surgically resectable...
6.
Tao M, Han J, Shi J, Liao H, Wen K, Wang W, et al.
J Hepatocell Carcinoma
. 2023 Jul;
10:1069-1083.
PMID: 37457652
Lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), is one of the preferred targeted drugs for the treatment of advanced hepatocellular carcinoma (aHCC). Since the REFLECT study showed that lenvatinib was...
7.
Huang P, Xu Q, Yan Y, Lu Y, Hu Z, Ou B, et al.
Oncogene
. 2023 Jun;
42(30):2361.
PMID: 37365220
No abstract available.
8.
Wen K, Yang F, Hu L, Shi J, Mui S, Wang W, et al.
Front Oncol
. 2023 Feb;
12:1031156.
PMID: 36776357
Background: The development of targeted therapy and immunotherapy has enriched the treatment of hepatocellular carcinoma (HCC), however, have had poor or no reponse, or even no response. Previous research suggested...
9.
Liu H, Yan Y, Lin J, He C, Liao H, Li H, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:788-802.
PMID: 36159591
Hepatitis B virus X protein (HBx) is considered as an oncogene in tumorigenesis and progression of hepatocellular carcinoma (HCC). In recent years, the important role of circular RNAs (circRNAs) in...
10.
Yu Z, Liu Q, Liao H, Shi J, Zhou Z, Yan Y, et al.
J Gastrointest Oncol
. 2022 May;
13(2):833-846.
PMID: 35557567
Background: The aim of the study was to establish and validate a novel prognostic nomogram of cancer-specific survival (CSS) in resected hilar cholangiocarcinoma (HCCA) patients. Methods: A training cohort of...